We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Leica Biosystems Launches Advanced Staining Solution for Increased Speed, Quality and Diagnostic Productivity

By LabMedica International staff writers
Posted on 02 Jun 2022

Leica Biosystems (Nussloch, Germany) has launched BOND-PRIME, a premium advanced staining solution, to advance diagnostic productivity in the lab. More...

BOND-PRIME is the only system that delivers all elements of universal access, enabling lab technicians to load any slides in any combination, with any reagent, at any time.

The BOND-PRIME staining platform was developed with the lab's needs in mind: in today's fast-paced health care environment, adaptability is essential to ensure that slides are processed in a timely manner. Universal Access on BOND-PRIME seamlessly adapts and optimizes workflow to stain slides as needed, leaving no slide staining position unutilized. BOND-PRIME features 70 open-access reagent positions and can process up to 72 slides seamlessly, helping to eliminate delays and facilitating continuous workflows.

Single or STAT slides may be turned around in as fast as one hour, enabling pathologists to deliver a diagnosis quickly to patients who need answers quickly. In addition to adaptability and speed, BOND-PRIME consistently delivers the crisp, clean stains that are needed for a definitive diagnosis. The instrument's progressive automation works in tandem with Novocastra premium reagents to produce crisp, high-quality staining in an average of 90 minutes.

"With IHC turnaround time shortened to an average of only 90 minutes, and 100% instrument utilization without constant attention, the BOND-PRIME stainer's impact on workflow is truly impressive," said Colin White, Senior Vice President of Advanced Staining and Imaging.

"We have a history of innovation to address customer needs," said Gustavo Perez-Fernandez, President at Leica Biosystems. "From ensuring STAT cases are processed efficiently, to decreasing the number of cases left pending, BOND-PRIME presents a quantifiable benefit to mid-sized and large laboratories."

Related Links:
Leica Biosystems 


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A blood biomarker test offers a clearer prognosis after cardiac arrest (Photo courtesy of Adobe Stock)

Blood Biomarker Improves Early Brain Injury Prognosis After Cardiac Arrest

After a cardiac arrest, many patients remain unconscious for days, leaving doctors and families facing uncertainty about whether meaningful recovery is possible. Current tools to assess brain damage, including... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.